Description
PIRIDE 2 TABLET is a widely prescribed oral hypoglycemic agent formulated with Glimepiride 2 mg, a second-generation sulfonylurea used in the treatment of Type 2 Diabetes Mellitus. It works by stimulating the pancreatic beta cells to release insulin, thereby reducing blood glucose levels effectively.
As part of a comprehensive diabetes management plan that includes diet, exercise, and regular monitoring, PIRIDE 2 TABLET plays a critical role in:
Lowering fasting and postprandial blood sugar levels
Improving long-term glycemic control (HbA1c reduction)
Reducing the risk of microvascular and macrovascular complications associated with uncontrolled diabetes
This formulation is especially suited for patients who require a higher strength of Glimepiride for effective glucose regulation. PIRIDE 2 TABLET can be used as monotherapy or in combination with other antidiabetic agents such as Metformin or insulin.
Contains Glimepiride 2 mg for moderate to advanced blood sugar management
Enhances insulin secretion in a glucose-dependent manner
Minimal risk of hypoglycemia when taken with meals
Improves insulin sensitivity at the cellular level
Convenient once-daily dosing for better patient compliance
PIRIDE 2 TABLET is manufactured in state-of-the-art facilities complying with WHO-GMP, ISO, and FDA certifications. Every batch undergoes strict quality control to ensure high efficacy, safety, and stability.
BLUEPILL EXPRESS is a globally recognized pharmaceutical company specializing in third-party manufacturing and international exports of quality medicines. With a presence in over 50 countries including Asia, Europe, Africa, North America, and Latin America, BLUEPILL EXPRESS is known for its reliable supply chain, premium formulations, and regulatory expertise.
PIRIDE 2 TABLET is part of the company’s comprehensive diabetes care portfolio, designed to meet the growing global demand for effective oral hypoglycemic agents.
Type 2 Diabetes Mellitus (non-insulin-dependent diabetes)
Adjunct to diet and exercise when monotherapy is insufficient
